# Exchange traded investment fund FinEx Developed Markets ex US UCITS ETF (USD)

FinEx

03/11/2025

**USD** share class

BLOOMBERG: SXUS200N index

USD share class

(ISIN: IE00BMDKNM37)

## **Index** Information

Index Ticker (Bloomberg) **SXUS200N index** 

Index Provider

**Solactive AG** 

Index Currency
USD

# **Key Information**

Product Name	FinEx Developed Markets ex US UCITS ETF (USD)	
ISIN	IE00BMDKNM37	
Issuer	FinEx Funds ICAV	
Inception Date	04/08/2021	
Fund Domicile	Ireland	
UCITS V Compliant	Yes	
Fund Manager	KBA Consulting Management Limited (Great Britain)	
Base Currency	USD	
Total Expence Ratio	0.90%	
Reference Index	Solactive GBS Developed Markets ex United States 200 USD Index NTR	
Custodian/Administrator	Citi Depositary Services (Ireland)/Citibank Europe	
EUSD Taxation	Out Of Scope	
Replication Method	Full replication	
Reporting Frequency	Semi-Annually	
Close of Fiscal Year	30-September	
Fund Auditor	Grant Thornton	
Trading Taxes	No UK Stamp duty or SDRT	
Currency Hedging	No	
Minimum Purchase	1 share	
NAV per share DD 03/10/2025	1.236484 USD	
Shares is Issue	34,300,000	
Total Fund Assets	42,655,582.64 USD	

# **Investment Objective**

The Fund aims to track the performance of the Solactive GBS Developed Markets ex United States 200 USD Index NTR (the "Index") before charges are applied to the Fund.

# **Trading Information**

Stock Exchange	Bloomberg Ticker	Bloomberg INAV
Irish Stock Exchange	FXDMID	FXDMUSIV Index

# Share class return for (USD, %)\*:




<sup>\*</sup>The yield is indicated in the fund's currency (U.S. dollar)


## **Contacts**

KBA Consulting Management Limited 35 Shelbourne Road Ballsbridge Dublin Ireland, D04 A4E0

## **Sector Allocation**



## **Geographic Allocation**



## **TOP 10 holdings**

Security	ISIN	Currency	Weight
SAP ORD	DE0007164600	EUR	2.114%
ASML HOLDING NV	NL0010273215	EUR	2.041%
NOVO NORDISK A/S-B	DK0062498333	DKK	2.040%
NESTLE SA-REG	CH0038863350	CHF	1.898%
ROCHE HLDG-GENUS	CH0012032048	CHF	1.753%
ASTRAZENECA ORD	GB0009895292	GBP	1.694%
NOVARTIS AG-REG	CH0012005267	CHF	1.569%
TOYOTA MOTOR ORD	JP3633400001	JPY	1.559%
HSBC HOLDINGS ORD	GB0005405286	GBP	1.488%
SHELL PLC-NEW	GB00BP6MXD84	GBP	1.458%

# **Authorized participants**

## **Goldenberg Hehmeyer LLP**

25 Canada Square, Canary Wharf London E14 5LB Tel: +44 (0) 207 390 33 35

## Jane Street

10 Chiswell Street London EC1Y 4UQ Tel: +44 (0) 203 100 34 00

## **FinEx Capital Management LLP**

25 Green Street, London W1 K 7AX Tel: +44 (0) 20 7663 3300 Email: info@finxcapital.com

## **Barclays Capital Securities Limited**

5 North Colonnade London E14 4BB Tel: +44 (0) 203 134 52 78

## **LLC C SAV Capital**

Khoroshevskoye highway, Moscow, 125284, Russia room 12/1, 32A, Tel: +7 495 568-12-19 Email: a.popovina@sav.capital

## Cifra broker LLC

18th floor, 1st Krasnogvardeysky proezd 15, Moscow, 123112, Russia Tel: +7 (495) 783-91-73 Email: info@cifra-broker.ru

Further information about FinEx Funds ICAV can be found in the prospectus and the supplement to the prospectus of the fund which is available at FinEx Group's website <a href="www.FinExETF.com">www.FinExETF.com</a>

## **GENERAL DISCLAIMER**

Investment in the products mentioned in this document may not be suitable for all investors. Past performance is not a guide to future performance and should not be the sole factor of consideration when selecting a product. The price of the investments may go up or down and the investor may not get back the amount invested. Your income is not fixed and may fluctuate. The value of investments involving exposure to foreign currencies can be affected by exchange rate movements. We remind you that the levels and bases of, and reliefs from, taxation can change. First Na not considered the suitability of this investment against your individual needs and risk tolerance. The data displayed provides summary information, investment should be made on the basis of the relevant Prospectus which is available from your Broker, Financial Adviser or First Investment Management LLP. We recommend you seek independent professional advice prior to investing. In respect of the products mentioned this document is intended for information purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from First Investment Management LLP.

FinEx Investment Management LLP, which is authorised and regulated by the Financial Conduct Authority ('FCA'), having its registered office at 4, Hill Street, London, WIJ 5NE, England, has issued this document. FinEx ETFs constitute exchange traded funds issued by an Irish domiciled company, FinEx Funds ICAV established under Irish law (the "Fund"). FinEx Funds ICAV (the "company") is an open-ended investment company with variable capital having segregated liability between their funds organised under the laws of Ireland and authorised by the Financial Regulator.

For professional investors in the UK: Please note that the Fund is not registered in the United Kingdom. Most of the protections provided by the UK regulatory system do not apply to the operation of the Company, and compensation will not be available under the UK Financial Services Compensation Scheme on its default. The Company is a recognised scheme for the purposes of the Financial Services and Markets Act

This document is not, and under no circumstances is to be construed as, an advertisement, or any other step in furtherance of a public offering of shares in the United States or Canada. This document is not aimed at persons who are resident in the United States, Canada or any province or territory thereof, where the Companies are not authorised or registered for distribution and where no prospectus for the Companies has been filed with any securities commission or regulatory authority. The Company may not be acquired or owned by, or acquired with the assets of, an ERISA Plan.

Barclays is a trademark of Barclays Bank PLC and is used by FinEx under licence. The Fund is not sponsored, endorsed, sold or promoted by Barclays and Barclays makes no representation regarding the advisability of investing in the Fund.